Lupin Limited (LUPIN) secures tentative approval from U.S. FDA for Enzalutamide Tablets, expanding dosage options.
Lupin Limited (NSE: LUPIN) launches Azilsartan Medoxomil Tablets in the U.S., following FDA approval, to treat hypertension.
Lupin Limited partners with LABORATORIOS ERN S.A. to launch Luforbec® in Spain, expanding respiratory care access.
Lupin Limited (LUPIN) and Natco Pharma receive FDA approval for Eribulin Mesylate Injection, a bioequivalent to Halaven®.
Lupin Limited (NSE: LUPIN) secures U.S. FDA approval for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets, marking a significant milestone.
Lupin Limited (LUPIN) shares positive Phase 1 data on LNP8701, a novel SOS1 inhibitor, accepted for ASCO Annual Meeting 2026.
Lupin Limited (LUPIN) receives Establishment Inspection Report (EIR) from U.S. FDA for its Ankleshwar facility, highlighting quality excellence.
Lupin Limited (LUPIN) secures China approval for Oseltamivir Phosphate Oral Suspension, marking its debut in the Chinese market.
Lupin Limited (LUPIN) makes its debut in Dow Jones Best-in-Class Indices 2026, highlighting its strong ESG performance and commitment to sustainability.
Lupin Limited (LUPIN) inaugurates Atharv Ability, a state-of-the-art neuro-rehabilitation center in Delhi, expanding access to advanced care for neurological disorders.